Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $12.7 million.

  • Prime Medicine's Share-based Compensation rose 8671.45% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year increase of 2499.59%. This contributed to the annual value of $26.1 million for FY2024, which is 8740.47% up from last year.
  • Prime Medicine's Share-based Compensation amounted to $12.7 million in Q3 2025, which was up 8671.45% from $6.3 million recorded in Q2 2025.
  • Prime Medicine's 5-year Share-based Compensation high stood at $12.7 million for Q3 2025, and its period low was $1.1 million during Q4 2021.
  • For the 5-year period, Prime Medicine's Share-based Compensation averaged around $4.5 million, with its median value being $4.3 million (2023).
  • As far as peak fluctuations go, Prime Medicine's Share-based Compensation skyrocketed by 20987.51% in 2024, and later plummeted by 2182.67% in 2025.
  • Prime Medicine's Share-based Compensation (Quarter) stood at $1.1 million in 2021, then skyrocketed by 132.52% to $2.6 million in 2022, then surged by 72.07% to $4.4 million in 2023, then soared by 34.14% to $5.9 million in 2024, then skyrocketed by 114.56% to $12.7 million in 2025.
  • Its Share-based Compensation was $12.7 million in Q3 2025, compared to $6.3 million in Q2 2025 and $5.7 million in Q1 2025.